First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...

The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in ...

Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...

Darlifarnib is an investigational next-generation farnesyl transferase inhibitor designed to interfere with cellular pathways ...

Data Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic Toxicity in Patients Diagnosed with Locally Advanced Pancreatic Cancer Metabolic Imaging, Used to ...

Sequential therapy strategies in oncogene-driven NSCLC. This figure illustrates a proposed therapeutic decision-making pathway for patients with NSCLC who develop acquired resistance after initial ...

Modern medicine is more advanced than ever, yet clinical care still leans heavily on what is, in practice, informed guesswork. Doctors make the most probable diagnosis, select the therapy most likely ...

While RMC is resistant to many common treatments, specific protocols have shown efficacy. Platinum-based chemotherapy remains a core treatment for RMC, and EGFR-targeting agents have been established ...

Targeted therapy is reaching more patients than ever, but access still depends on factors like cost, insurance coverage, geography, and cancer type. These treatments offer precision and strong ...

Mixed histiocytosis (Langerhans cell histiocytosis [LCH] / Erdheim-Chester disease [ECD]) developing after treatment for ...